Production (Stage)
ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -50.11% | -18.46% | -8.68% | 22.57% | 9.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.89% | -64.67% | -50.82% | -57.55% | -45.99% |
| Operating Income | 71.89% | 64.67% | 50.82% | 57.55% | -323.62% |
| Income Before Tax | 69.15% | 61.29% | 35.05% | 55.65% | -352.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.15% | 61.29% | 35.05% | 55.65% | -352.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.15% | 61.29% | 35.05% | 55.65% | -352.24% |
| EBIT | 71.89% | 64.67% | 50.82% | 57.55% | -323.62% |
| EBITDA | 73.97% | 65.95% | 51.99% | 58.73% | -301.92% |
| EPS Basic | 74.71% | 68.32% | 39.49% | 63.17% | -262.38% |
| Normalized Basic EPS | 74.68% | 69.13% | 52.60% | 62.78% | -262.38% |
| EPS Diluted | 74.71% | 68.32% | 39.49% | 63.17% | -274.71% |
| Normalized Diluted EPS | 74.68% | 69.13% | 52.60% | 62.78% | -271.22% |
| Average Basic Shares Outstanding | 21.92% | 22.22% | 7.33% | 20.40% | 55.37% |
| Average Diluted Shares Outstanding | 21.92% | 22.22% | 7.33% | 20.40% | 47.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |